Maged Mostafa Mahmoud1,2,3, Modhi Alenezi4,5, Ahmed M Al-Hejin6, Turki S Abujamel2,7, Fadwa Aljoud1, Abdulwahab Noorwali1,4, Ibrahim A Awad8, Mohammed Alkhaled9, Haitham A Yacoub10. 1. Regerenative Medicine Unit, King Fahd Medical Research Center, King Abdulaziz University, P.O. Box 80216, 21589, Jeddah, SA, Saudi Arabia. 2. Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, KAU, 21589, Jeddah, SA, Saudi Arabia. 3. Molecular Genetics and Enzymology Department, Human Genetics Division and Genome Research Institute, National Research Centre, Cairo, Egypt. 4. Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, 21589, Jeddah, Saudi Arabia. 5. Faculty of Applied Medical Sciences, Northern Border University, 73221 Arar, Saudi Arabia. 6. Biological Sciences Department, Faculty of Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. 7. Vaccines and Immunotherapy Unit, King Fahd Medical Research Center (KFMRC), King Abdulaziz University (KAU), 21589, Jeddah, SA, Saudi Arabia. 8. Department of Diagnostic Radiology Technology, Faculty of Applied Medical Sciences, KAU, 21589, Jeddah, SA, Saudi Arabia. 9. Biological Sciences Department, Faculty of Sciences, University of Jeddah, Jeddah, Saudi Arabia. 10. Cell Biology Department, Biotechnology Research Institute, National Research Centre, 33 El Bohouth St., Dokki, P.O. 12622, Giza, Egypt. ha.mohamed@nrc.sci.eg.
Abstract
BACKGROUND: This study served as the pioneer in studying the anti-cancer role of chicken cathelicidin peptides. METHODS AND RESULTS: Chicken cathelicidins were used as anticancer agent against the breast cancer cell line (MCF-7) and human colon cancer cell line (HCT116). In addition, the mechanism of action of the interaction of cationic peptides with breast cancer cell line MCF-7 was also investigated. An in vivo investigation was also achieved to evaluate the role of chicken cathelicidin in Ehrlich ascites cell (EAC) suppression as a tumor model after subcutaneous implantation in mice. It was found during the study that exposure of cell lines to 40 µg/ml of chicken cathelicidin for 72 h reduced cell lines growth rate by 90-95%. These peptides demonstrated down-regulation of (cyclin A1 and cyclin D genes) of MCF-7 cells. The study showed that two- and three-fold expression of both of caspase-3 and - 7 genes in untreated MCF-7 cells compared to treated MCF-7 cells with chicken cathelicidin peptides. Our data showed that chicken (CATH-1) enhance releasing of TNFα, INF-γ and upregulation of granzyme K in treated mice groups, in parallel, the tumor size and volume was reduced in the treated EAC-bearing groups. Tumor of mice groups treated with chicken cathelicidin displayed high area of necrosis compared to untreated EAC-bearing mice. Based on histological analysis and immunohistochemical staining revealed that the tumor section in Ehrlich solid tumor exhibited a strong Bcl2 expression in untreated control compared to mice treated with 10 & 20 µg of cathelicidin. Interestingly, low expression of Bcl2 were observed in mice taken 40 µg/mL of CATH-1. CONCLUSIONS: This study drive intention in treatment of cancer through the efficacy of anticancer efficacy of chicken cathelicidin peptides.
BACKGROUND: This study served as the pioneer in studying the anti-cancer role of chicken cathelicidin peptides. METHODS AND RESULTS: Chicken cathelicidins were used as anticancer agent against the breast cancer cell line (MCF-7) and human colon cancer cell line (HCT116). In addition, the mechanism of action of the interaction of cationic peptides with breast cancer cell line MCF-7 was also investigated. An in vivo investigation was also achieved to evaluate the role of chicken cathelicidin in Ehrlich ascites cell (EAC) suppression as a tumor model after subcutaneous implantation in mice. It was found during the study that exposure of cell lines to 40 µg/ml of chicken cathelicidin for 72 h reduced cell lines growth rate by 90-95%. These peptides demonstrated down-regulation of (cyclin A1 and cyclin D genes) of MCF-7 cells. The study showed that two- and three-fold expression of both of caspase-3 and - 7 genes in untreated MCF-7 cells compared to treated MCF-7 cells with chicken cathelicidin peptides. Our data showed that chicken (CATH-1) enhance releasing of TNFα, INF-γ and upregulation of granzyme K in treated mice groups, in parallel, the tumor size and volume was reduced in the treated EAC-bearing groups. Tumor of mice groups treated with chicken cathelicidin displayed high area of necrosis compared to untreated EAC-bearing mice. Based on histological analysis and immunohistochemical staining revealed that the tumor section in Ehrlich solid tumor exhibited a strong Bcl2 expression in untreated control compared to mice treated with 10 & 20 µg of cathelicidin. Interestingly, low expression of Bcl2 were observed in mice taken 40 µg/mL of CATH-1. CONCLUSIONS: This study drive intention in treatment of cancer through the efficacy of anticancer efficacy of chicken cathelicidin peptides.
Authors: Yuxin Chen; Colin T Mant; Susan W Farmer; Robert E W Hancock; Michael L Vasil; Robert S Hodges Journal: J Biol Chem Date: 2005-01-27 Impact factor: 5.157
Authors: William K K Wu; Guangshun Wang; Seth B Coffelt; Aline M Betancourt; Chung W Lee; Daiming Fan; Kaichun Wu; Jun Yu; Joseph J Y Sung; Chi H Cho Journal: Int J Cancer Date: 2010-10-15 Impact factor: 7.396